Bioavailable Testosterone: The Pool of Hormone Cells Can Actually Reach
Bioavailable testosterone is the portion of testosterone in your bloodstream that can readily reach and activate cells. Testosterone is made primarily in the testes and ovaries, with a smaller amount from the adrenal glands. In blood, most testosterone is bound tightly to a carrier protein, sex hormone–binding globulin (SHBG), which keeps it largely unavailable. A smaller share is loosely bound to albumin and a tiny amount circulates unbound. Bioavailable testosterone combines the free fraction and the albumin‑bound fraction—the physiologically accessible pool measured by a blood test.
This biomarker reflects the hormone that can actually interact with tissues and influence androgen‑dependent processes. It helps gauge the capacity for effects such as sexual function and fertility, maintenance of muscle and bone, red blood cell production, body composition, and aspects of mood and energy (androgen activity at the androgen receptor). Because it represents what is available to cells rather than the total carried in the blood, it offers a closer view of functional testosterone status across different ages and in all sexes.
Why a Functional Androgen Measure Beats Total Testosterone
Bioavailable testosterone is the fraction that can actually reach cells—free plus loosely albumin‑bound hormone—so it most appropriate reflects real‑world androgen activity in muscle, bone, brain, blood, skin, and reproductive tissues. It integrates testicular/ovarian production with binding by SHBG, making it a more functional signal than total testosterone when SHBG is abnormal (obesity, thyroid or liver disease, medications, pregnancy).
Big picture: bioavailable testosterone is a nexus biomarker linking the hypothalamic‑pituitary‑gonadal axis with metabolism, bone, mood, and fertility. Persistently low or high levels point to broader endocrine or metabolic issues and track long‑term risks such as osteoporosis, anemia, infertility, and cardiometabolic disease.
How a Bioavailable Testosterone Result Maps to Symptoms
Reference ranges vary by age, sex, and lab. In adult men, feeling well often aligns with values in the mid‑to‑upper part of the lab range; in premenopausal women, normal is much lower and closer to the low end. During adolescence values change rapidly. In pregnancy, total testosterone rises while SHBG rises even more, so bioavailable levels and interpretation differ.
When bioavailable testosterone is low, it may reflect reduced gonadal output or excess SHBG. Men can experience low libido, reduced morning erections, fatigue, depressed mood, loss of muscle and bone, anemia, and increased visceral fat and insulin resistance. Women may notice lower sexual desire, reduced exercise capacity, and bone or mood effects; in boys it can delay pubertal progression.
When it is high, men may have acne, oily skin, irritability, elevated red blood cell count, sleep‑disordered breathing, and suppressed sperm production; causes include anabolic use, tumors, or low SHBG states. In women, high values suggest hyperandrogenism (often PCOS), with hirsutism, acne, scalp hair thinning, irregular cycles, and metabolic risk; in girls it can cause virilization.
What Shifts a Bioavailable Testosterone Value
Notes: SHBG and albumin strongly shape results. Many labs calculate bioavailable testosterone from total T, SHBG, and assumed albumin; methods differ. Levels peak in the morning and fall with acute illness. Age, pregnancy, thyroid/liver disease, obesity/insulin resistance, and oral estrogens or androgens shift SHBG; use sex‑, age‑, and pregnancy‑specific ranges.
What a Bioavailable Testosterone Number Adds to the Hormonal Picture
Bioavailable testosterone is the fraction of testosterone that can readily reach cells—the free hormone plus the albumin‑bound portion, not the tightly SHBG‑bound pool. It reflects the active androgen signal that supports energy metabolism, muscle and bone maintenance, red blood cell production, libido and fertility, mood and cognition, fat distribution, and cardiometabolic and immune balance.
Low values usually reflect reduced testicular/ovarian production or excess binding from high SHBG. In men, often with aging or hyperthyroidism/estrogen exposure, it links to fatigue, low libido and morning erections, loss of muscle and bone, anemia, more fat, and lower insulin sensitivity. In women, it may show as low sexual desire, reduced strength, and low mood. Pregnancy raises SHBG, lowering bioavailable relative to total.
Being in range suggests sufficient androgen signaling for stable energy, body composition, bone strength, hematologic health, and sexual function without hyperandrogenic effects. There is no single appropriate, but symptom‑free values generally sit mid‑range for age and sex; men often track mid‑to‑upper, women low‑to‑mid.
High values usually reflect increased androgen production or low SHBG. In women, this often accompanies polycystic ovary syndrome and less commonly adrenal/ovarian tumors or congenital adrenal hyperplasia, with hirsutism, acne, scalp hair thinning, and ovulatory dysfunction, plus higher cardiometabolic risk. In men, causes include androgen use, tumors, or low SHBG states (obesity, insulin resistance, hypothyroidism), with acne, erythrocytosis, mood changes, and prostate enlargement.
FAQs
It measures the free plus albumin-bound fraction of testosterone to capture the hormone that is actually available to tissues.
It aligns results with how you feel and perform, especially when SHBG shifts make total testosterone misleading.
Test periodically, especially when adjusting training, lifestyle, or therapy, and repeat at consistent times to track trends.
Age, thyroid status, liver health, insulin resistance, weight, sleep, training, nutrition, alcohol, stress, medications, and SHBG shifts.
Morning testing is preferred for consistency. Fasting is not usually required unless paired with other labs.
Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.
We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.
References
- Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A. (2018). Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism, 103(5), 1715-1744. https://doi.org/10.1210/jc.2018-00229
- Travison, T. G., Vesper, H. W., Orwoll, E., Wu, F., Kaufman, J. M., Wang, Y., Lapauw, B., Fiers, T., Matsumoto, A. M., & Bhasin, S. (2017). Harmonized reference ranges for circulating testosterone levels in men of four cohort studies in the United States and Europe. The Journal of Clinical Endocrinology and Metabolism, 102(4), 1161-1173. https://doi.org/10.1210/jc.2016-2935
- Selby, C. (1990). Sex hormone binding globulin: Origin, function and clinical significance. Annals of Clinical Biochemistry, 27(6), 532-541. https://doi.org/10.1177/000456329002700603
- Stener-Victorin, E., Teede, H., Norman, R. J., Legro, R., Goodarzi, M. O., Dokras, A., Laven, J., Hoeger, K., & Piltonen, T. T. (2024). Polycystic ovary syndrome. Nature Reviews Disease Primers, 10(1), 27. https://doi.org/10.1038/s41572-024-00511-3
- Gasbarrino, K., Daly, E., & Daskalopoulou, S. S. (2022). An LC-MS/MS methodological framework for steroid hormone measurement from human serum. Hormone and Metabolic Research, 54(5), 300-307. https://doi.org/10.1055/a-1768-0709






































.avif)
